Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics’ earnings for the second fiscal quarter of 2026 missed consensus on EPS, with -$1.01 trailing the -$0.97 estimate by -$0.04, as the company posted sharply lower revenue alongside continued operating losses in results reported August 5, 2026. Revenue fell -53.9% year over year to roughly $0.9 million (down from about $1.9 million a year ago), and gross profit also came in at roughly $0.9 million. Operating income was about -$45.0 million, while net income was -$42.8 million, up ~1% from about -$43.1 million a year ago. On a per-share basis, EPS of -$1.01 improved ~3% from -$1.04 in the prior-year quarter even as it came in below the Street’s expectation. For the next period, consensus calls for EPS of -$0.98 on revenue of $2.1 million.